Interest Rate Swaps In order to minimize financing costs and to manage interest rate exposure, from time to time, we enter into interest rate swap agreements.
In December 2005, we entered into forward swap agreements to hedge interest rate exposure related to $500 million of term financing to be executed during 2006.
In February 2006, we terminated a forward swap agreement hedging the anticipated execution of $250 million of term financing because the transaction was no longer expected to occur by the originally specified time period or within an additional two-month period of time thereafter.
We recorded a gain of $1.0 million in the first quarter of 2006 as a result of the discontinuance of this cash flow hedge.
In August 2006, a forward swap agreement hedging the anticipated issuance of $250 million of 10-year notes matured resulting in cash receipts of $3.7 million.
The $3.7 million gain on the swap will be amortized as a reduction to interest expense over the term of the $250 million of 5.45% Notes due September 1, 2016.
In October 2003, we entered into swap agreements effectively converting interest payments on long-term debt from fixed to variable rates.
We converted interest payments on $200 million of 6.7% Notes due in October 2005 and $150 million of 6.95% Notes due in March 2007 from their respective fixed rates to variable rates based on the London Interbank Offered Rate, LIBOR.
In March 2004, we terminated these agreements, resulting in cash receipts totaling $5.2 million, with a corresponding increase to the carrying value of the long-term debt.
We amortized this increase over the terms of the respective long-term debt as a reduction to interest expense.
As of December 31, 2007, and 2006 we were not a party to any interest rate swap agreements.
Foreign Exchange Forward Contracts We enter into foreign exchange forward contracts to hedge transactions denominated in foreign currencies.
These transactions are primarily purchase commitments or forecasted purchases of equipment, raw materials and finished goods.
We also may hedge payment of forecasted intercompany transactions with our subsidiaries outside the United States.
These contracts reduce currency risk from exchange rate movements.
We generally hedge foreign currency price risks for periods from 3 to 24 months.
Foreign exchange forward contracts are effective as hedges of identifiable, foreign currency commitments.
We designate our foreign exchange forward contracts as cash flow hedging derivatives.
The fair value of these contracts is classified as either an asset or liability on the Consolidated Balance Sheets.
We record gains and losses on these contracts as a component of other comprehensive income and reclassify them into earnings in the same period during which the hedged transaction affects earnings.
A summary of foreign exchange forward contracts and the corresponding amounts at contracted forward rates is as follows:
## Table 0 ##
## Table 1 ##
THE HERSHEY COMPANY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued) · We base the risk-free interest rate for periods within the contractual life of the option on the U. S.  Treasury yield curve in effect at the time of grant.
·“Expected lives” means the period of time that options granted are expected to be outstanding based primarily on historical data.
Stock Options The exercise price of each option equals the market price of the Company’s Common Stock on the date of grant.
Prior to approval by our stockholders of the EICP on April 17, 2007, the exercise price of stock options granted under the former Key Employee Incentive Plan was determined as the closing price of our Common Stock on the New York Stock Exchange on the trading day immediately preceding the date the stock options were granted.
Following approval of the EICP, the exercise price is the closing price of our Common Stock on the New York Stock Exchange on the date of the grant.
Each option has a maximum term of ten years.
Options granted to executives and key employees prior to December 31, 1999, vested at the end of the second year after grant.
In 2000, we changed the terms and conditions of the grants to provide for pro-rated vesting over four years for options granted subsequent to December 31, 1999.
## Table 2 ##
In 2007, compensation cost was reduced by $1.1 million related to stock option forfeitures from the global supply chain transformation program.
The 2006 compensation amount included $1.2 million for the impact of the modification of stock option grants resulting in accelerated vesting of stock options.
In 2005, this amount was $3.9 million.
The modification related to employees exiting our Company in 2006 and 2005 under the terms of the voluntary workforce reduction program.
A summary of the status of our Company’s stock options and changes during the years ending on those dates follows:
## Table 3 ##
ILLUMINA, INC.  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) Executive Deferred Compensation Plan For the Company’s executives and members of the board of directors, the Company adopted the Illumina, Inc.
Deferred Compensation Plan (the Plan) that became effective January 1, 2008.
Eligible participants can contribute up to 80% of their base salary and 100% of all other forms of compensation into the Plan, including bonus, commission and director fees.
The Company has agreed to credit the participants’ contributions with earnings that reflect the performance of certain independent investment funds.
On a discretionary basis, the Company may also make employer contributions to participant accounts in any amount determined by the Company.
The vesting schedules of employer contributions are at the sole discretion of the Compensation Committee.
However, all employer contributions shall become 100% vested upon the occurrence of the participant’s disability, death or retirement or a change in control of the Company.
The benefits under this plan are unsecured.
Participants are generally eligible to receive payment of their vested benefit at the end of their elected deferral period or after termination of their employment with the Company for any reason or at a later date to comply with the restrictions of Section 409A.
As of December 28, 2008, no employer contributions were made to the Plan.
In January 2008, the Company also established a rabbi trust for the benefit of its directors and executives under the Plan.
In accordance with FASB Interpretation (FIN) No.46, Consolidation of Variable Interest Entities, an Interpretation of ARB No.51, and EITF 97-14, Accounting for Deferred Compensation Arrangements Where Amounts Earned Are Held in a Rabbi Trust and Invested, the Company has included the assets of the rabbi trust in its consolidated balance sheet since the trust’s inception.
As of December 28, 2008, the assets of the trust and liabilities of the Company were $1.3 million.
The assets and liabilities are classified as other assets and accrued liabilities, respectively, on the Company’s balance sheet as of December 28, 2008.
Changes in the values of the assets held by the rabbi trust accrue to the Company.14.
Segment Information, Geographic Data and Significant Customers During the first quarter of 2008, the Company reorganized its operating structure into a newly created Life Sciences Business Unit, which includes all products and services related to the research market, namely the BeadArray, BeadXpress and Sequencing product lines.
The Company also created a Diagnostics Business Unit to focus on the emerging opportunity in molecular diagnostics.
For the year ended December 28, 2008, the Company had limited activity related to the Diagnostics Business Unit, and operating results were reported on an aggregate basis to the chief operating decision maker of the Company, the chief executive officer.
In accordance with SFAS No.131, Disclosures about Segments of an Enterprise and Related Information, the Company operated in one reportable segment for the year ended December 28, 2008.
The Company had revenue in the following regions for the years ended December 28, 2008, December 30, 2007 and December 31, 2006 (in thousands):

Tables referenced above, in order (Table 0 first):
<table><tr><td> December 31,</td><td colspan="2"> 2007</td><td colspan="2"> 2006</td></tr><tr><td> Primary  Currencies</td><td> In millions of dollars Foreign exchange forward contracts to purchase foreign currencies</td><td></td><td></td><td></td></tr><tr><td>Australian dollars Canadian dollars Euros</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Foreign exchange forward contracts to sell foreign currencies</td><td>$86.7</td><td>Canadian dollars Brazilian reais Mexican pesos</td><td></td></tr></table>
<table><tr><td rowspan="2"> December 31,</td><td colspan="2"> 2007</td><td colspan="2"> 2006</td></tr><tr><td> Contract  Amount</td><td> Primary  Currencies</td><td> Contract  Amount</td><td> Primary  Currencies</td></tr><tr><td> In millions of dollars</td><td></td><td></td><td></td><td></td></tr><tr><td>Foreign exchange forward contracts to purchase foreign currencies</td><td> $13.8</td><td>British pounds Australian dollars Euros</td><td>$29.0</td><td>Australian dollars Canadian dollars Euros</td></tr><tr><td>Foreign exchange forward contracts to sell foreign currencies</td><td> $86.7</td><td>Canadian dollars Brazilian reais Mexican pesos</td><td></td><td></td></tr></table>
<table><tr><td> For the years ended December 31,</td><td> 2007</td><td> 2006</td><td> 2005</td></tr><tr><td> In millions of dollars</td><td></td><td></td><td></td></tr><tr><td>Compensation amount charged against income for stock options</td><td>$26.8</td><td>$33.4</td><td>$38.2</td></tr></table>
<table><tr><td></td><td colspan="2"> 2007</td><td colspan="2"> 2006</td><td colspan="2"> 2005</td></tr><tr><td> Stock Options</td><td>Shares</td><td> Weighted- Average Exercise Price</td><td>Shares</td><td> Weighted- Average Exercise Price</td><td>Shares</td><td> Weighted- Average Exercise Price</td></tr><tr><td>Outstanding at beginning of year</td><td>13,855,113</td><td>$40.29</td><td>13,725,113</td><td>$37.83</td><td>14,909,536</td><td>$32.82</td></tr><tr><td>Granted</td><td>2,240,883</td><td>$53.72</td><td>1,777,189</td><td>$52.43</td><td>2,051,255</td><td>$61.49</td></tr><tr><td>Exercised</td><td>-1,686,448</td><td>$29.97</td><td>-1,269,690</td><td>$28.68</td><td>-2,898,419</td><td>$28.14</td></tr><tr><td>Forfeited</td><td>-520,432</td><td>$52.29</td><td>-377,499</td><td>$47.19</td><td>-337,259</td><td>$43.54</td></tr><tr><td>Outstanding at end of year</td><td>13,889,116</td><td>$43.26</td><td>13,855,113</td><td>$40.29</td><td>13,725,113</td><td>$37.83</td></tr><tr><td>Options exercisable at year-end</td><td>8,316,966</td><td>$37.43</td><td>8,212,209</td><td>$34.39</td><td>7,001,941</td><td>$30.86</td></tr><tr><td>Weighted-average fair value of options granted during the year (per share)</td><td>$12.84</td><td></td><td>$15.07</td><td></td><td>$16.90</td><td></td></tr></table>

Question: Does the proportion of Outstanding at beginning of year for Shares in total larger than that of Granted in 2007?
Answer: Yes